Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Dec;104(4):797–804. doi: 10.1111/j.1476-5381.1991.tb12509.x

Effects of endothelin-1 on vascular permeability in the conscious rat: interactions with platelet-activating factor.

J G Filep 1, M G Sirois 1, A Rousseau 1, A Fournier 1, P Sirois 1
PMCID: PMC1908850  PMID: 1667286

Abstract

1. The objectives of the present experiments were to assess the effects of endothelin-1 on the macrovascular permeability in selected vascular beds, to study the involvement of platelet-activating factor (PAF) in vascular responses to endothelin-1 and to examine the vascular effects of combined administration of endothelin-1 and PAF in conscious rats. 2. Intravenous bolus injection of endothelin-1 (0.1-2 nmol kg-1) resulted in a dose-dependent biphasic change in mean arterial blood pressure (MABP) with initial transient hypotension followed by a prolonged pressor action. These changes were accompanied by a dose-dependent increase in haematocrit values. 3. Endothelin-1 (0.1 and 1 nmol kg-1) increased dose-dependently the vascular permeability of the trachea, upper and lower bronchi, stomach, duodenum, spleen and kidney (up to 240%) as measured by the extravasation of Evans blue dye. The permeability of pulmonary parenchyma, liver and pancreas was not affected significantly by endothelin-1 treatment. 4. Pretreatment of animals with the specific PAF receptor antagonist, WEB 2086 (1 mg kg-1, i.v.) or BN 52021 (10 mg kg-1, i.v.) reduced the endothelin-1 (1 nmol kg-1)-induced rise in haematocrit by about 50 and 30%, respectively. Both antagonists were highly effective at inhibiting protein extravasation in the stomach, duodenum and kidney. On the other hand, BN 52021, but not WEB 2086, significantly attenuated the effect of endothelin-1 on permeability in the lower bronchi and spleen. Neither WEB 2086 nor BN 52021 modified the changes in MABP evoked by endothelin-1.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
797

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amelang E., Prasad C. M., Raymond R. M., Grega G. J. Interactions among inflammatory mediators on edema formation in the canine forelimb. Circ Res. 1981 Aug;49(2):298–306. doi: 10.1161/01.res.49.2.298. [DOI] [PubMed] [Google Scholar]
  2. Armstead W. M., Mirro R., Leffler C. W., Busija D. W. Influence of endothelin on piglet cerebral microcirculation. Am J Physiol. 1989 Aug;257(2 Pt 2):H707–H710. doi: 10.1152/ajpheart.1989.257.2.H707. [DOI] [PubMed] [Google Scholar]
  3. Battistini B., Sirois P., Braquet P., Filep J. G. Endothelin-induced constriction of guinea pig airways: role of platelet-activating factor. Eur J Pharmacol. 1990 Sep 21;186(2-3):307–310. doi: 10.1016/0014-2999(90)90449-g. [DOI] [PubMed] [Google Scholar]
  4. Björk J., Smedegård G. Acute microvascular effects of PAF-acether, as studied by intravital microscopy. Eur J Pharmacol. 1983 Dec 9;96(1-2):87–94. doi: 10.1016/0014-2999(83)90532-0. [DOI] [PubMed] [Google Scholar]
  5. Borić M. P., Donoso V., Fournier A., St Pierre S., Huidobro-Toro J. P. Endothelin reduces microvascular blood flow by acting on arterioles and venules of the hamster cheek pouch. Eur J Pharmacol. 1990 Nov 6;190(1-2):123–133. doi: 10.1016/0014-2999(90)94119-i. [DOI] [PubMed] [Google Scholar]
  6. Brain S. D., Crossman D. C., Buckley T. L., Williams T. J. Endothelin-1: demonstration of potent effects on the microcirculation of humans and other species. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S147–S150. [PubMed] [Google Scholar]
  7. Brain S. D., Tippins J. R., Williams T. J. Endothelin induces potent microvascular constriction. Br J Pharmacol. 1988 Dec;95(4):1005–1007. doi: 10.1111/j.1476-5381.1988.tb11731.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Casals-Stenzel J., Muacevic G., Weber K. H. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. J Pharmacol Exp Ther. 1987 Jun;241(3):974–981. [PubMed] [Google Scholar]
  9. Chander C. L., Moore A. R., Desa F. M., Howat D. W., Willoughby D. A. Anti-inflammatory effects of endothelin-1. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S218–S219. doi: 10.1097/00005344-198900135-00064. [DOI] [PubMed] [Google Scholar]
  10. D'Orleans-Juste P., Finet M., de Nucci G., Vane J. R. Pharmacology of endothelin-1 in isolated vessels: effect of nicardipine, methylene blue, hemoglobin, and gossypol. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S19–S45. [PubMed] [Google Scholar]
  11. Dahlöf B., Gustafsson D., Hedner T., Jern S., Hansson L. Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction. J Hypertens. 1990 Sep;8(9):811–817. doi: 10.1097/00004872-199009000-00004. [DOI] [PubMed] [Google Scholar]
  12. Doebber T. W., Wu M. S., Robbins J. C., Choy B. M., Chang M. N., Shen T. Y. Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone. Biochem Biophys Res Commun. 1985 Mar 29;127(3):799–808. doi: 10.1016/s0006-291x(85)80014-0. [DOI] [PubMed] [Google Scholar]
  13. Filep J. G., Battistini B., Sirois P. Pharmacological modulation of endothelin-induced contraction of guinea-pig isolated airways and thromboxane release. Br J Pharmacol. 1991 Jul;103(3):1633–1640. doi: 10.1111/j.1476-5381.1991.tb09840.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Filep J., Földes-Filep E., Frölich J. C. Vascular responses to leukotriene B4, C4 and D4 following FPL 55712, indomethacin, saralasin, phentolamine and verapamil in the conscious rat. Br J Pharmacol. 1987 Feb;90(2):431–439. doi: 10.1111/j.1476-5381.1987.tb08973.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Filep J., Hermán F., Braquet P., Mózes T. Increased levels of platelet-activating factor in blood following intestinal ischemia in the dog. Biochem Biophys Res Commun. 1989 Jan 31;158(2):353–359. doi: 10.1016/s0006-291x(89)80055-5. [DOI] [PubMed] [Google Scholar]
  16. Furchgott R. F., Zawadzki J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980 Nov 27;288(5789):373–376. doi: 10.1038/288373a0. [DOI] [PubMed] [Google Scholar]
  17. Földes-Filep E., Braquet P., Filep J. Inhibition by BN 52021 (ginkgolide B) of the binding of [3H]-platelet-activating factor to human neutrophil granulocytes. Biochem Biophys Res Commun. 1987 Nov 13;148(3):1412–1417. doi: 10.1016/s0006-291x(87)80289-9. [DOI] [PubMed] [Google Scholar]
  18. Goetz K. L., Wang B. C., Madwed J. B., Zhu J. L., Leadley R. J., Jr Cardiovascular, renal, and endocrine responses to intravenous endothelin in conscious dogs. Am J Physiol. 1988 Dec;255(6 Pt 2):R1064–R1068. doi: 10.1152/ajpregu.1988.255.6.R1064. [DOI] [PubMed] [Google Scholar]
  19. Grega G. J., Adamski S. W., Dobbins D. E. Physiological and pharmacological evidence for the regulation of permeability. Fed Proc. 1986 Feb;45(2):96–100. [PubMed] [Google Scholar]
  20. Handley D. A., Van Valen R. G., Melden M. K., Saunders R. N. Evaluation of dose and route effects of platelet activating factor-induced extravasation in the guinea pig. Thromb Haemost. 1984 Aug 31;52(1):34–36. [PubMed] [Google Scholar]
  21. Kubes P., Ibbotson G., Russell J., Wallace J. L., Granger D. N. Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence. Am J Physiol. 1990 Aug;259(2 Pt 1):G300–G305. doi: 10.1152/ajpgi.1990.259.2.G300. [DOI] [PubMed] [Google Scholar]
  22. Lagente V., Chabrier P. E., Mencia-Huerta J. M., Braquet P. Pharmacological modulation of the bronchopulmonary action of the vasoactive peptide, endothelin, administered by aerosol in the guinea-pig. Biochem Biophys Res Commun. 1989 Feb 15;158(3):625–632. doi: 10.1016/0006-291x(89)92767-8. [DOI] [PubMed] [Google Scholar]
  23. Maron M. B. Differential effects of histamine on protein permeability in dog lung and forelimb. Am J Physiol. 1982 Apr;242(4):H565–H572. doi: 10.1152/ajpheart.1982.242.4.H565. [DOI] [PubMed] [Google Scholar]
  24. McIntyre T. M., Zimmerman G. A., Satoh K., Prescott S. M. Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate. J Clin Invest. 1985 Jul;76(1):271–280. doi: 10.1172/JCI111957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Moncada S., Gryglewski R., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976 Oct 21;263(5579):663–665. doi: 10.1038/263663a0. [DOI] [PubMed] [Google Scholar]
  26. Montrucchio G., Alloatti G., Tetta C., De Luca R., Saunders R. N., Emanuelli G., Camussi G. Release of platelet-activating factor from ischemic-reperfused rabbit heart. Am J Physiol. 1989 Apr;256(4 Pt 2):H1236–H1246. doi: 10.1152/ajpheart.1989.256.4.H1236. [DOI] [PubMed] [Google Scholar]
  27. Morel D. R., Lacroix J. S., Hemsen A., Steinig D. A., Pittet J. F., Lundberg J. M. Increased plasma and pulmonary lymph levels of endothelin during endotoxin shock. Eur J Pharmacol. 1989 Aug 29;167(3):427–428. doi: 10.1016/0014-2999(89)90454-8. [DOI] [PubMed] [Google Scholar]
  28. Moreno R. H., Hogg J. C., Paré P. D. Mechanics of airway narrowing. Am Rev Respir Dis. 1986 Jun;133(6):1171–1180. doi: 10.1164/arrd.1986.133.6.1171. [DOI] [PubMed] [Google Scholar]
  29. Mózes T., Braquet P., Filep J. Platelet-activating factor: an endogenous mediator of mesenteric ischemia-reperfusion-induced shock. Am J Physiol. 1989 Oct;257(4 Pt 2):R872–R877. doi: 10.1152/ajpregu.1989.257.4.R872. [DOI] [PubMed] [Google Scholar]
  30. Scherf H., Nies A. S., Schwertschlag U., Hughes M., Gerber J. G. Hemodynamic effects of platelet activating factor in the dog kidney in vivo. Hypertension. 1986 Sep;8(9):737–741. doi: 10.1161/01.hyp.8.9.737. [DOI] [PubMed] [Google Scholar]
  31. Simonson M. S., Dunn M. J. Endothelin peptides: a possible role in glomerular inflammation. Lab Invest. 1991 Jan;64(1):1–4. [PubMed] [Google Scholar]
  32. Sirois M. G., Plante G. E., Braquet P., Sirois P. Role of eicosanoids in PAF-induced increases of the vascular permeability in rat airways. Br J Pharmacol. 1990 Dec;101(4):896–900. doi: 10.1111/j.1476-5381.1990.tb14177.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Szabo S., Trier J. S., Brown A., Schnoor J. Early vascular injury and increased vascular permeability in gastric mucosal injury caused by ethanol in the rat. Gastroenterology. 1985 Jan;88(1 Pt 2):228–236. doi: 10.1016/s0016-5085(85)80176-1. [DOI] [PubMed] [Google Scholar]
  34. Takayasu M., Kondo K., Terao S. Endothelin-induced mobilization of Ca2+ and the possible involvement of platelet activating factor and thromboxane A2. Biochem Biophys Res Commun. 1989 Apr 28;160(2):751–757. doi: 10.1016/0006-291x(89)92497-2. [DOI] [PubMed] [Google Scholar]
  35. Terashita Z., Shibouta Y., Imura Y., Iwasaki K., Nishikawa K. Endothelin-induced sudden death and the possible involvement of platelet activating factor (PAF). Life Sci. 1989;45(20):1911–1918. doi: 10.1016/0024-3205(89)90545-6. [DOI] [PubMed] [Google Scholar]
  36. Voelkel N. F., Chang S. W., Pfeffer K. D., Worthen S. G., McMurtry I. F., Henson P. M. PAF antagonists: different effects on platelets, neutrophils, guinea pig ileum and PAF-induced vasodilation in isolated rat lung. Prostaglandins. 1986 Sep;32(3):359–372. doi: 10.1016/0090-6980(86)90005-5. [DOI] [PubMed] [Google Scholar]
  37. Waite R. P., Pang C. C. Effects of endothelin on arterial pressure and venous tone in intact and hexamethonium-treated conscious rats. J Cardiovasc Pharmacol. 1990 Dec;16(6):940–944. doi: 10.1097/00005344-199012000-00012. [DOI] [PubMed] [Google Scholar]
  38. Warner T. D. Simultaneous perfusion of rat isolated superior mesenteric arterial and venous beds: comparison of their vasoconstrictor and vasodilator responses to agonists. Br J Pharmacol. 1990 Feb;99(2):427–433. doi: 10.1111/j.1476-5381.1990.tb14720.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Watanabe T., Suzuki N., Shimamoto N., Fujino M., Imada A. Endothelin in myocardial infarction. Nature. 1990 Mar 8;344(6262):114–114. doi: 10.1038/344114a0. [DOI] [PubMed] [Google Scholar]
  40. Yamamoto J., Trippodo N. C., Ishise S., Frohlich E. D. Total vascular pressure-volume relationship in the conscious rat. Am J Physiol. 1980 Jun;238(6):H823–H828. doi: 10.1152/ajpheart.1980.238.6.H823. [DOI] [PubMed] [Google Scholar]
  41. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]
  42. Yang Z. H., Bühler F. R., Diederich D., Lüscher T. F. Different effects of endothelin-1 on cAMP- and cGMP-mediated vascular relaxation in human arteries and veins: comparison with norepinephrine. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S129–S142. doi: 10.1097/00005344-198900135-00032. [DOI] [PubMed] [Google Scholar]
  43. Yasuda M., Kohno M., Tahara A., Itagane H., Toda I., Akioka K., Teragaki M., Oku H., Takeuchi K., Takeda T. Circulating immunoreactive endothelin in ischemic heart disease. Am Heart J. 1990 Apr;119(4):801–806. doi: 10.1016/s0002-8703(05)80315-1. [DOI] [PubMed] [Google Scholar]
  44. de Nucci G., Thomas R., D'Orleans-Juste P., Antunes E., Walder C., Warner T. D., Vane J. R. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9797–9800. doi: 10.1073/pnas.85.24.9797. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES